Key Highlights

  • Specialty pharmacy Revenue reached $109 million, up 44 percent year over year.
  • Specialty pharmacy gross Margin was 24 percent.
  • Capitated revenue grew 40 percent, and the company expects about $110 million of capitated revenue in 2026.
  • The company updated its full-year 2026 guidance.

Starling Oncology (NASDAQ:STLN), described as one of the largest value-based community oncology groups in the United States, reported financial results for the quarter ended September 30, 2026, and updated its full-year 2026 guidance. Specialty pharmacy revenue was $109 million, up 44 percent year over year, with a gross margin of 24 percent. Capitated revenue, which relates to fixed per-patient payments under value-based arrangements, grew 40 percent.

Specialty Pharmacy and Capitated Growth

The specialty pharmacy Business grew 44 percent, a faster rate than capitated revenue's 40 percent. Its 24 percent gross margin is the reference point for how much of each dollar of pharmacy revenue remains after cost of goods, which affects how the segment contributes to overall profitability.

Capitated revenue rose 40 percent, and the company said its medical loss ratio is performing at expectations. For capitated arrangements, the medical loss ratio measures the share of capitated premiums spent on patient care, so performing at expectations indicates that patient cost management is in line with the company's plan.

Full-Year Outlook

The company expects approximately $110 million of capitated revenue in 2026 and updated its full-year guidance in the release.

Because capitated revenue depends on the number of patients under contract and on per-patient rates, its growth rate is sensitive to enrollment decisions and contract terms. The projected full-year figure gives a reference point for the second half of 2026.

Sector Context and What to Watch

Community oncology groups and value-based care providers operate under reimbursement models that combine fee-for-service revenue with fixed payments. Their results depend on patient mix, drug costs and the management of care utilization.

Final Takeaways

Starling Oncology reported 44 percent growth in specialty pharmacy revenue and 40 percent growth in capitated revenue, with its updated full-year guidance providing the next reference point. The company's margin profile and cost management in capitated arrangements will shape its results. Subsequent quarters will indicate whether these trends continue.